Article Sidebar
Main Article Content
Unraveling the Mysteries of Autoimmune Gastritis
Main Article Content
Abstract
Autoimmune gastritis is an immune-mediated disease characterized by the destruction of parietal cells and atrophy of the oxyntic mucosa due to anti-parietal cell antibodies. It may lead to serious conditions including iron/vitamin B12 and micronutrient deficiencies, neurological disorders, and gastric malignancies. The exact mechanism of this disease is not exactly understood; however, dysregulated immunological mechanisms appear to be major contributors. Patients with this disease are often asymptomatic but may present with gastrointestinal symptoms and/or iron/vitamin B12 deficiencies. Although important serological markers are available and despite advanced endoscopic techniques, the definitive diagnosis relies on histopathological examination of gastric corporal biopsy specimens. Autoimmune gastritis is closely related with increased risk of gastric neuroendocrine tumors and gastric adenocarcinoma. Patients with autoimmune gastritis do not benefit from specific treatments, thus, management is directed to restore micronutrient deficiencies and to prevent occurrence of neoplastic transformation with appropriate endoscopic surveillance.
Cite this article as: Soykan İ, Er RE, Baykara Y, Kalkan C. Unraveling the mysteries of autoimmune gastritis. Turk J Gastroenterol. 2025;36(3):135-144.
Article Details
References
1. Toh BH, Chan J, Kyaw T, Alderuccio F. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol. 2012;42(3):269-278. [CrossRef]
2. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr. 2016;166(13-14):424-430. [CrossRef]
3. Miceli E, Vanoli A, Lenti MV, et al. Natural history of autoimmune atrophic gastritis: a prospective, single centre, long term experience. Aliment Pharmacol Ther. 2019;50(11-12):1172-1180. [CrossRef]
4. Martinelli TM, van Driel IR, Alderuccio F, Gleeson PA, Toh BH. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology. 1996;110(6):1791-1802. [CrossRef]
5. Massironi S, Zilli A, Elvevi A, Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun Rev. 2019;18(3):215-222. [CrossRef]
6. D’Elios MM, Bergman MP, Azzurri A, et al. H(+), K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology. 2001;120(2):377-386. [CrossRef]
7. Vergelli M, Hemmer B, Muraro PA, et al. Human autoreactive CD4 T cell clones use perforin or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol. 1997;158(6):2756-2761. [CrossRef]
8. Lahner E, Spoletini M, Buzzetti R, et al. HLADRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Dig Liver Dis. 2010;42(12):854-859. [CrossRef]
9. Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+,K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med. 2003;198(8):1147-1156. [CrossRef]
10. Karlsson FA, Burman P, Lööf L, Mårdh S. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+,K+-adenosine triphosphatase of the stomach. J Clin Invest. 1988;81(2):475-479. [CrossRef]
11. Wang L, Cao ZM, Zhang LL, et al. Helicobacter pylori and autoimmune diseases: involving multiple systems. Front Immunol. 2022;13:833424. [CrossRef]
12. De Re V, Repetto O, De Zorzi M, et al. Polymorphism in toll-like receptors and Helicobacter pylori motility in autoimmune atrophic gastritis and gastric cancer. Cancers. 2019;11(5):648. [CrossRef]
13. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis: pathogenesis, pathology, and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529-541. [CrossRef]
14. Soykan I, Yakut M, Keskin O, Bektaş M. Clinical profiles, endoscopic and laboratory features and associated factors in patients with autoimmune gastritis. Digestion. 2012;86(1):20-26. [CrossRef]
15. Kalkan Ç, Soykan I, Soydal Ç, Özkan E, Kalkan E. Assessment of gastric emptying in patients with autoimmune gastritis. Dig Dis Sci. 2016;61(6):1597-1602. [CrossRef]
16. Carabotti M, Lahner E, Esposito G, Sacchi MC, Severi C, Annibale B. Upper gastrointestinal symptoms in autoimmune gastritis: a cross-sectional study. Medicine. 2017;96(1):e5784. [CrossRef]
17. Tenca A, Massironi S, Pugliese D, et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. Neurogastroenterol Motil. 2016;28(2):274-280. [CrossRef]
18. Pilotto V, Maddalo G, Orlando C, et al. Objective evidence of gastro-esophageal reflux disease is rare in patients with autoimmune gastritis. J Gastrointestin Liver Dis. 2021;30(1):30-36. [CrossRef]
19. Yakut M, Keskin O, Soykan I. Effect of endogenous hypergastrinemia on gallbladder volume and ejection fraction in patients with autoimmune gastritis. Hepatobiliary Pancreat Dis Int. 2012;11(5):527-531. [CrossRef]
20. Stojanovich L. Autonomic dysfunction in autoimmune rheumatic disease. Autoimmun Rev. 2009;8(7):569-572. [CrossRef]
21. Kalkan Ç, Soydal Ç, Özkan E, Maden A, Soykan I. Relationships between autonomic nerve function and gastric emptying in patients with autoimmune gastritis. Clin Auton Res. 2016;26(3):189-196. [CrossRef]
22. Kalkan Ç, Soykan I. The relations among serum ghrelin, motilin and gastric emptying and autonomic function in autoimmune gastritis. Am J Med Sci. 2018;355(5):428-433. [CrossRef]
23. Kalkan Ç, Soykan I. Polyautoimmunity in autoimmune gastritis. Eur J Intern Med. 2016;31:79-83. [CrossRef]
24. Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: a challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. [CrossRef]
25. Lenti MV, Miceli E, Vanoli A, Klersy C, Corazza GR, Di Sabatino A. Time course and risk factors of evolution from potential to overt autoimmune gastritis. Dig Liver Dis. 2022;54(5):642-644. [CrossRef]
26. Kalkan Ç, Soykan I. Differences between older and young patients with autoimmune gastritis. Geriatr Gerontol Int. 2017;17(7):1090-1095. [CrossRef]
27. De Block CEM, De Leeuw IH, Bogers JJPM, et al. Autoimmune gastropathy in type-1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care. 2003;26(1):82-88. [CrossRef]
28. Greenson JK, Lauwers GY, Montgomery EA, Owens SR, Polydorides AE. Diagnostic Pathology: Gastrointestinal. 3rd ed. Amsterdam, The Netherlands: Elsevier; 2019:140-143.
29. Itsuno M, Watanabe H, Iwafuchi M, et al. Multiple carcinoids and endocrine cell micronests in type A gastritis: their morphology, histogenesis, and natural history. Cancer. 1989;63(5):881-890. [CrossRef]
30. Miceli E, Lenti MV, Gentile A, et al. Long-Term Natural History of Autoimmune Gastritis: results from a prospective monocentric series. Am J Gastroenterol. 2024;119(5):837-845. [CrossRef]
31. Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657-667. [CrossRef]
32. Kishino M, Nonaka K. Endoscopic features of autoimmune gastritis: focus on typical images and early images. J Clin Med. 2022;11(12):3523. [CrossRef]
33. Terao S, Suzuki S, Yaita H, et al. Multicenter study of autoimmune gastritis in Japan: clinical and endoscopic characteristics. Dig Endosc. 2020;32(3):364-372. [CrossRef]
34. Krasinskas AM, Abraham SC, Metz DC, Furth EE. Oxyntic mucosa pseudopolyps: a presentation of atrophic autoimmune gastritis. Am J Surg Pathol. 2003;27(2):236-241. [CrossRef]
35. Massironi S, Gallo C, Lahner E, et al. Occurrence and characteristics of endoscopic gastric polyps in patients with autoimmune gastritis (AGAPE study): a multicentric cross-sectional study. Dig Liver Dis. 2024. S1590-8658(24)00887-9. [CrossRef]
36. Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018;48(3):370-377. [CrossRef]
37. Kotera T. Characteristic endoscopic findings in early-stage autoimmune gastritis. Endosc Int Open. 2024;123:E332-E338.
38. Dottori L, Corleone Tsar’kov DC, Dilaghi E, et al. Efficacy and safety of intravenous ferric carboxymaltose treatment of iron deficiency anaemia in patients with corpus atrophic gastritis: a retrospective study. Nutrients. 2023;15(19):4199. [CrossRef]
39. Snook J, Bhala N, Beales ILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030-2051. [CrossRef]
40. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. 2009;15(41):5121-5128. [CrossRef]
41. Conti L, Borro M, Milani C, et al. Gastric microbiota composition in patients with corpus atrophic gastritis. Dig Liver Dis. 2021;53(12):1580-1587. [CrossRef]
42. Conti L, Annibale B, Lahner E. Autoimmune gastritis and gastric microbiota. Microorganisms. 2020;8(11):1827. [CrossRef]
43. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO Classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. [CrossRef]
44. Li T-T, Qiu F, Qian ZR, Wan J, Qi X-K, Wu B-Y. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20(1):118-125. [CrossRef]
45. Panzuto F, Ramage J, Pritchard DM, et al. European Neuroendocrine Tumor Society (ENETS) 2023 Guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J Neuroendocrinol. 2023;35(8):e13306. [CrossRef]
46. Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020;12(8):791-807. [CrossRef]
47. Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6(1):56. [CrossRef]
48. Massironi S, Gallo C, Laffusa A, et al. Endoscopic techniques for gastric neuroendocrine tumors: an update. World J Gastrointest Endosc. 2023;15(3):103-113. [CrossRef]
49. Roberto GA, Rodrigues CMB, Peixoto RD, Younes RN. Gastric neuroendocrine tumor: a practical literature review. World J Gastrointest Oncol. 2020;12(8):850-856. [CrossRef]
50. Exarchou K, Hu H, Stephens NA, et al. Endoscopic surveillance alone is feasible and safe in Type I gastric neuroendocrine neoplasms less than 10 mm in diameter. Endocrine. 2022;78(1):186-196. [CrossRef]
51. Tsolakis AV, Ragkousi A, Vujasinovic M, Kaltsas G, Daskalakis K. Gastric neuroendocrine neoplasms Type 1: a systematic review and meta-analysis. World J Gastroenterol. 2019;25(35):5376-5387. [CrossRef]
52. Zilli A, Arcidiacono PG, Conte D, Massironi S. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Dig Liver Dis. 2018;50(1):6-14. [CrossRef]
53. Deprez PH, Moons LMG, O’Toole D, et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2022;54(4):412-429. [CrossRef]
54. Boyce M, Moore AR, Sagatun L, et al. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol. 2017;83(3):466-475. [CrossRef]
55. Rossi RE, Invernizzi P, Mazzaferro V, Massironi S. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent Type-1 gastric carcinoids: a systematic review and meta-analysis. U Eur Gastroenterol J. 2020;8(2):140-147. [CrossRef]
56. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology. 2021;161(4):1325-1332.e7. [CrossRef]
57. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011;117(6):1163-1171. [CrossRef]
58. Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients. Gut. 2023;72(1):30-38. [CrossRef]
59. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. [CrossRef]